仙琚制药(002332) - 2018 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period reached CNY 891,329,243.77, a year-on-year increase of 24.69%[8] - Net profit attributable to shareholders increased by 47.83% to CNY 88,364,696.46 for the reporting period[8] - Basic earnings per share rose by 42.86% to CNY 0.10[8] - The net profit attributable to shareholders for the year-to-date period was CNY 211,667,094.16, reflecting a 50.18% increase[8] - The net profit attributable to shareholders for 2018 is expected to increase by 30.00% to 60.00%, ranging from 26,861.91 to 33,060.82 million CNY[20] Assets and Liabilities - Total assets increased by 9.20% to CNY 5,606,778,444.21 compared to the end of the previous year[8] - Accounts receivable increased by 48.68%, up by 29,809.31 million CNY, mainly due to sales revenue growth and seasonal impacts in the industry[16] - Deferred income increased by 182.68%, up by 8,381.4 million CNY, mainly due to receiving policy relocation compensation[16] - Other receivables increased by 48.53%, up by 1,110.95 million CNY, mainly due to an increase in other temporary payments[16] Cash Flow and Expenses - Net cash flow from operating activities surged by 284.81% to CNY 151,213,433.16[8] - Cash paid to employees increased by 30.08%, up by 8,935.27 million CNY, due to higher salary expenses[17] - Cash paid for taxes increased by 40.7%, up by 7,747.55 million CNY, due to higher tax payments during the period[17] - Cash paid for fixed assets increased by 111.57%, up by 11,881.51 million CNY, primarily due to increased investments in fixed assets[17] Shareholder Information - The company reported a total of 29,339 common shareholders at the end of the reporting period[12] - The largest shareholder, Xianju County State-owned Assets Investment Group, holds 21.55% of the shares[12] - The company did not engage in any repurchase transactions during the reporting period[13] Research and Development - R&D expenses increased by 77.41%, up by 3,635.24 million CNY, attributed to higher R&D spending during the period[17] Commitments and Compliance - The company has no overdue commitments or non-operating fund occupation by controlling shareholders during the reporting period[19]